GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) » Definitions » Total Assets

Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Total Assets : $70.05 Mil (As of Jun. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Total Assets?

Santhera Pharmaceuticals Holding AG's Total Assets for the quarter that ended in Jun. 2023 was $70.05 Mil.

During the past 12 months, Santhera Pharmaceuticals Holding AG's average Total Assets Growth Rate was -8.50% per year. During the past 3 years, the average Total Assets Growth Rate was -9.30% per year. During the past 5 years, the average Total Assets Growth Rate was 0.50% per year. During the past 10 years, the average Total Assets Growth Rate was 34.50% per year.

During the past 13 years, Santhera Pharmaceuticals Holding AG's highest 3-Year average Total Assets Growth Rate was 109.80%. The lowest was -48.90%. And the median was 1.05%.

Total Assets is connected with ROA %. Santhera Pharmaceuticals Holding AG's annualized ROA % for the quarter that ended in Jun. 2023 was -74.87%. Total Assets is also linked to Revenue through Asset Turnover. Santhera Pharmaceuticals Holding AG's Asset Turnover for the quarter that ended in Jun. 2023 was 0.06.


Santhera Pharmaceuticals Holding AG Total Assets Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Total Assets Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 111.20 117.09 99.83 98.93 68.41

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.36 98.93 82.23 68.41 70.05

Santhera Pharmaceuticals Holding AG Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Santhera Pharmaceuticals Holding AG's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets=Total Equity (A: Dec. 2022 )+Total Liabilities (A: Dec. 2022 )
=-46.894+115.298
=68.40

Santhera Pharmaceuticals Holding AG's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets=Total Equity (Q: Jun. 2023 )+Total Liabilities (Q: Jun. 2023 )
=-47.492+117.544
=70.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) Total Assets Explanation

Total Assets is connected with ROA %.

Santhera Pharmaceuticals Holding AG's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %=Net Income (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=-51.834/( (68.405+70.052)/ 2 )
=-51.834/69.2285
=-74.87 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Santhera Pharmaceuticals Holding AG's Asset Turnover for the quarter that ended in Jun. 2023 is

Asset Turnover
=Revenue (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=4.375/( (68.405+70.052)/ 2 )
=4.375/69.2285
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Santhera Pharmaceuticals Holding AG Total Assets Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.